Poster Session E - Tuesday Afternoon
Category: IBD
Joelle BouSaba, MD
Mayo Clinic
Rochester, MN
All patients (n=93) | |
Age, in years, mean (SD) | 30 (15) |
Sex assigned at birth, Female, N(%) | 59 (63) |
Sexual orientation, N(%) | |
Bisexual | 48 (52) |
Gay/lesbian/homosexual | 39 (42) |
Other | 5 (5) |
Prefer not to disclose | 1(1) |
Gender Identity, N(%) | |
Female | 52 (56) |
Male | 30 (32) |
Genderqueer | 2 (2) |
Transgender female | 2 (2) |
Other | 7 (8) |
Race, N(%) | |
White | 85 (92) |
Black | 3 (3) |
American indian/Alaska native | 1 (1) |
Asian | 1 (1) |
Native Hawaiian/Pacific Native Islander | 1 (1) |
Other | 2 (2) |
IBD diagnosis, N(%) | |
Ulcerative colitis | 48 (52) |
Crohn's Disease | 45 (48) |
IBD medications at initial visit, (n=37) | |
Mesalamine | 20 (54) |
Corticosteroids | 15 (41) |
Thiopurines | 10 (27) |
Infliximab | 8 (21) |
Adalimumab | 7 (19) |
Vedolizumab | 2 (5) |
Ustekinumab | 2 (5) |
Certolizomab | 2 (5) |
Methotrexate | 1 (3) |